Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Beijing Inno Medicine Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. All matters are assigned to 1 distinct examiner and 1 distinct art unit, so prosecution activity is concentrated in a single examination path.
DICKINSON, PAUL W is the busiest identified examiner, with 3 pending matters. A focused response strategy and close continuity in communications may be useful because the entire pending set is associated with that examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 3 | 63.2% | +9.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18530122 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 72d overdue |
| 19388923 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | — |
| 19030601 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19388923 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 1618 | §103§112Other | Non-Final OA | — | Pending | Nov 13, 2025 |
| 19030601 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 1618 | §102§112 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18530122 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | DICKINSON, PAUL W | 1618 | §103§112 | Non-Final OA | 72d overdue | Pending | Dec 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Inno Medicine Co. Ltd. has 3 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul W Dickinson has the most, with 3 of Beijing Inno Medicine Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
